Dear Editor,
Managing perioperative pain remains a central challenge in anesthesiology, particularly when adequate analgesia must be balanced against opioid-related adverse effects and the risk of persistent opioid use. Although opioids remain valuable analgesics, their use may be complicated by respiratory depression, sedation, tolerance, dependence, and opioid-induced hyperalgesia (OIH). Contemporary perioperative recommendations therefore emphasize individualized multimodal analgesia, appropriate opioid prescribing, and the assessment of functional recovery rather than pain intensity alone (1-3). In this context, natural products may offer a promising source of candidate compounds for investigating nociceptive mechanisms and opioid-associated neurobehavioral effects. However, their potential therapeutic value must be distinguished from clinical benefits demonstrated through rigorous investigation.
Evidence from experimental pain research suggests that natural compounds may influence pathways involved in nociception. For example, formononetin has been investigated for its analgesic effects and the possible involvement of hypothalamic corticotrophin-releasing hormone, orexin, and melanin-concentrating hormone signaling in a rat pain model (4). A review of phytochemicals and plant-derived natural products has also described potential analgesic mechanisms involving inflammatory signaling, neuronal excitability, and ion channels associated with nociceptive transmission (5). These findings support further investigation of molecular and neuroendocrine pathways as potential targets for analgesic development. Nevertheless, experimental analgesic activity does not establish efficacy in postoperative pain. The clinical relevance of these findings depends on reproducibility, pharmacokinetic characterization, dose optimization, and safety evaluation. Studies should also determine whether candidate compounds interact with opioids or commonly used anesthetic agents in ways that alter analgesia, sedation, or respiratory function.
Another relevant area is opioid dependence and withdrawal. Research on Ganoderma lucidum extract in mice has explored its effects on morphine dependence (6), while a systematic review of randomized clinical trials has examined herbal therapies for opioid withdrawal syndrome (7). Together, these studies illustrate the potential of natural-product research to identify compounds that influence opioid-associated behavioral and physiological responses. However, dependence, withdrawal, tolerance, OIH, and persistent postoperative opioid use are distinct phenomena. Evidence of an effect on withdrawal-related behavior cannot, by itself, demonstrate that a compound reduces postoperative opioid consumption or prevents OIH. Future investigations should define these outcomes separately and establish whether any observed benefits persist without compromising analgesia or introducing additional adverse effects.
Research on natural-product-based adjuncts in local anesthesia provides an additional clinically relevant perspective. A randomized clinical trial comparing lidocaine alone with lidocaine combined with clove oil for episiotomy-site anesthesia illustrates the evaluation of a natural product in conjunction with a conventional local anesthetic (8). Such studies are valuable because they assess an intervention in a clinical setting. Nevertheless, findings from episiotomy-site anesthesia cannot automatically be generalized to peripheral nerve blocks, neuraxial anesthesia, or general anesthesia. Before broader clinical adoption, potential adjuncts require evaluation of their formulation, local tolerability, systemic exposure, and interactions with the primary anesthetic. Adequate assessment of adverse events is particularly important when a natural product is combined with an established drug.
The potential effects of natural products on the central nervous system also warrant careful consideration. Experimental work has examined the protective effects of Echium amoenum seed oil against pentylenetetrazole-induced seizures (9). Similarly, research on Phoenix dactylifera L. pollen and fluvoxamine in PC12 cells exposed to hydrogen peroxide has explored oxidative stress and the expression of Nrf2 and SIGMAR1 (10). Although these studies may inform hypotheses regarding neurological effects, neuronal protection, and cellular defense mechanisms, they do not establish protection against anesthesia-related neurological complications or improved postoperative cognitive outcomes. Candidate compounds therefore require targeted neurological and toxicological evaluation before potential perioperative applications can be established.
These findings have practical implications for translational research. First, the chemical composition of botanical extracts and the identities and concentrations of their active constituents should be characterized to support quality control, batch consistency, and reproducibility. Second, pharmacokinetic, toxicological, and drug-interaction assessments should inform clinical development, particularly when candidate compounds may affect central nervous system function or interact with perioperative medications. Third, preclinical models should incorporate behavioral outcomes relevant to the intended clinical application to improve the translational value of analgesic research (11). For perioperative analgesic candidates, clinical evaluation should include relevant outcomes such as postoperative pain intensity, physical function, and treatment-related adverse events (12). Rescue analgesic requirements and opioid consumption should also be measured directly when an opioid-sparing effect is hypothesized, rather than inferred from biochemical markers or experimental pain responses (1, 2, 12).
Clinical development should be guided by established principles of perioperative pain management. Multimodal analgesia and individualized opioid prescribing remain central to minimizing opioid-related harm (1, 2). The addition of a natural product should therefore be evaluated against appropriate standard-of-care comparators and should not replace established analgesics without adequate evidence. Early-phase studies should prioritize safety, tolerability, pharmacokinetics, and potential interactions; subsequent controlled trials should assess clinically meaningful benefits and harms. Longer follow-up may also be needed when investigators claim that an intervention reduces persistent postoperative opioid use or improves longer-term recovery.
In conclusion, natural products offer promising opportunities for identifying pharmacological leads relevant to pain processing and opioid-associated neurobehavioral outcomes. However, the available evidence from experimental pain models, dependence and withdrawal studies, neurological investigations, and cell-based experiments supports further investigation rather than routine clinical use. A translational framework combining chemical standardization, mechanistic validation, interaction studies, and appropriately designed clinical trials could help identify candidates with genuine value for anesthesiology and perioperative medicine. Maintaining a clear distinction between biological plausibility and demonstrated clinical efficacy will be essential to realizing this potential safely.
